MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

113.72
-0.41
-0.36%
After Hours: 114.00 +0.28 +0.25% 18:54 09/18 EDT
OPEN
114.39
PREV CLOSE
114.13
HIGH
114.77
LOW
109.80
VOLUME
3.64M
TURNOVER
--
52 WEEK HIGH
121.50
52 WEEK LOW
72.67
MARKET CAP
24.92B
P/E (TTM)
30.47
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average ALXN stock price target is 141.32 with a high estimate of 175.00 and a low estimate of 114.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALXN
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.